Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma

Chenguang Jia, Jie Zheng, Meng Yuan, Hongbo He, Yibo Fan, Bin Wang, Guanghua Zhu, Jun Yang, Yanhui Luo, Lixiao Cai, Pan Zhang, Yanlong Duan, Maoquan Qin
Pediatric Investigation · Wiley · 2026-07-08 · DOI: 10.1002/ped4.70070

Abstract

ABSTRACT Importance The prognosis of pediatric refractory/relapsed non‐Hodgkin lymphoma (R/R NHL) remains poor, with limited evidence guiding optimal treatment. Haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) is a promising strategy for this high‐risk population. However, the optimal conditioning regimen and long‐term outcomes of haplo‐HSCT have not been fully elucidated. Objective To evaluate the long‐term efficacy and safety of antithymocyte globulin (ATG)‐based myeloablative haplo‐HSCT in pediatric patients with R/R NHL. Methods Pediatric patients with R/R NHL who underwent ATG‐based myeloablative haplo‐HSCT at Beijing Children's Hospital between March 2015 and December 2021 were retrospectively enrolled. Overall survival (OS) and progression‐free survival (PFS) were estimated using the Kaplan–Meier method and compared using the log‐rank test. Results A total of 29 pediatric R/R NHL patients were enrolled, including 21 with lymphoblastic lymphoma and 8 with mature T‐cell and natural killer–cell lymphoma. The 5‐year OS, PFS, cumulative incidence of relapse, and non‐relapse mortality were 79.3%, 72.4%, 10.0%, and 17.0%, respectively. At a median follow‐up of 5.5 years, the cumulative incidences of Grade III–IV acute graft‐versus‐host disease (GVHD) and chronic GVHD were 13.8% (4/29) and 44.8% (13/29; predominantly mild), respectively. Thrombotic microangiopathy (TMA) developed in 12 patients and was associated with significantly inferior prognosis ( P = 0.001). Interpretation ATG‐based myeloablative haplo‐HSCT is a safe and effective treatment for pediatric R/R NHL, offering a viable alternative for patients lacking matched donors or requiring urgent intervention. Early detection and timely treatment of TMA may reduce mortality and improve survival outcomes.

Read at publisher →

Similar articles